JAZZ | NASDAQ
Next Earnings: Apr 02, 2026
Company Overview:
7 Year JAZZ Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 months FREE!
JAZZ Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for JAZZ
Based on past 7-year performance, here are JAZZ growth metrics:
Share price CAGR of +4.48%
Dividend CAGR of +0%
Using JAZZ CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| JAZZ (DRIP) | JAZZ - No DRIP | |
|---|---|---|
| Current Price | $186.35 | $186.35 |
| Start Shares | 53.66 | 53.66 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 53.66 | 53.66 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $276.45 | $186.35 |
| Total Dividends | $0 | $0 |
| Final Value | $14,835 | $10,000 |
NOTE: Above numbers are our estimate based on JAZZ's Dividend and Price CAGR over past 7 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 months FREE!
Company Info
Jazz Pharmaceuticals plc (JAZZ) had its IPO on 2007-06-01, and is trader on NASDAQ stock exchange.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ website: https://www.jazzpharma.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 months FREE!
